CAMBRIDGE, Mass.– C4 Therapeutics today announced the appointment of Andrew Phillips, Ph.D. as Chief Scientific Officer. Dr. Phillips joins from the Broad Institute of MIT and Harvard and will lead C4 Therapeutics’ research efforts and the development of proprietary therapeutics based on the Company’s groundbreaking Degronimid™ platform. The Degronimid™ technology utilizes highly selective small molecule binders to target disease-causing proteins and leverages the cell’s ubiquitin/proteasome system to facilitate their rapid destruction and clearance.
“Dr. Phillips is an accomplished leader in the field of ligand discovery for the most challenging of targets and his extensive experience in the development of promising therapeutic candidates and in building scientific alliances at the Broad Institute is directly in line with C4’s mission to translate our Degronimid™ platform into a new class of medicines,” said Jason Fisherman, M.D., President and Chief Executive Officer of C4. “We will greatly benefit from Dr. Phillips’ synthetic chemistry and biochemistry expertise to support our industry partnerships and the development of our own proprietary pipeline of therapeutics based on targeted protein degradation (TPD).”
“I am honored to join the talented leadership team of C4 where I have the opportunity to shape the company’s research programs and participate in its rapid growth,” said Dr. Phillips. “TPD therapeutics, created with our innovative Degronimid™ platform, have enormous potential to unlock previously intractable disease targets and make a major impact on human health.”
Prior to joining C4, Dr. Phillips was Senior Director, Center for Development of Therapeutics at Broad Institute of MIT and Harvard, where he led overall therapeutic efforts and provided strategic leadership for a number of major partnerships. Previously, he was a Full Professor of Chemistry at Yale University, where he received the ACS Cope Scholar Award for his research accomplishments, which included the development of small molecules aimed at modulating ‘undruggable’ targets. Prior to this, he was a Full Professor of Chemistry and Biochemistry at the University of Colorado at Boulder, where his efforts in complex molecule synthesis and targeting protein-protein interactions garnered a number of awards, including an Alfred P. Sloan Research Fellowship, Eli Lilly Grantee Award, and a National Science Foundation CAREER Award.
Dr. Phillips received a B.Sc. (Hons) in biochemistry and a Ph.D. in biochemistry and chemistry from the University of Canterbury in New Zealand and completed a postdoctoral fellowship in organic chemistry at the University of Pittsburgh.
About C4 Therapeutics
C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs.
More information about C4 Therapeutics is available at www.C4Therapeutics.com.
MacDougall Biomedical Communications
Kari Watson, 781-235-3060